

09/110,376

-3-

Patent Office website showed that a patent has still not issued on the above-identified application.

Enclosed is an Information Disclosure Statement, which shows testing of the presence of various B-cell markers but which also shows negative results for the presence of the CD8 product on human colon tumor cells. Accordingly, to accord with these test results, claim 1 has been split into claims 1 and 6 directed to human breast and human colon tumors respectively, and only the products which have been proven for the respective tumors are listed therefor.

It is therefore respectfully submitted that this application is in condition for allowance, and such is respectfully requested.

Respectfully submitted,

*James C. Simmons*  
James C. Simmons  
Reg. no. 28,474

Enclosures

The Law Office of James C. Simmons  
11 Falmouth Lane  
Williamsville, NY 14221  
Phone (716) 632-7702

09/110,376

-4-

## Version with Markings to Show Changes Made

In the Claim:

Claim 1 has been amended as follows:

Claim 1 (four times amended). A method of predicting the lymphotropic metastatic potential of a primary human breast or ~~colon~~ tumor, the method comprising obtaining a plurality of representative samples of the tumor and determining for at least one product selected from the group consisting of TCR $\beta$ , CD3, CD4, and CD8, ~~and ZAP-70~~ the percentage of tumor cells of each of the samples which express said at least one product, wherein the tumor is predicted to have substantially no metastatic potential when no tumor cells in all of the samples are detected to express said at least one product.

The following claim has been added:

6. A method of predicting the lymphotropic metastatic potential of a primary human colon tumor, the method comprising obtaining a plurality of representative samples of the tumor and determining for at least one product selected from the group consisting of TCR $\beta$ , CD4, and ZAP-70 the percentage of tumor cells of each of the samples which express said at least one product, wherein the tumor is predicted to have substantially no metastatic potential when no tumor cells in all of the samples are detected to express said at least one product.